A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.

Inclusion Criteria

• •Prior treatment with at least 2 anti-hypertensive medications, at optimal or best tolerated dose, of different pharmacological classes, including a diuretic,
• •Participants with uncontrolled blood pressure (mean sitting systolic blood pressure of 140 mmHg or greater) and chronic kidney disease stage 3 or 4 (estimated Glomerular Filtration Rate of at least 15 and below 60 mL/min/1.73m2 using the Chronic Kidney Disease-Epidemiology equation),
• •Women of childbearing potential are eligible only if the following applies:
• •* Negative pregnancy test at the screening visit and at baseline (i.e., end of run-in period).
• •* Agree to undertake pregnancy tests during the study and up to 30 days after randomized study treatment discontinuation.
• •* Agree to use highly-effective methods of contraception up to at least 30 days after study treatment discontinuation.